Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells by Kim, Tae-Ho et al.
© 2011 Kim et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2011:6 2621–2631
International Journal of Nanomedicine
Preparation of polylactide-co-glycolide 
nanoparticles incorporating celecoxib and their 
antitumor activity against brain tumor cells
Tae-Ho Kim1*
Young-Il Jeong2*
Shu-Guang Jin2
Jian Pei2
Tae-Young Jung1
Kyung-Sub Moon1
In-Young Kim1
Sam-Suk Kang1
Shin Jung1,2
1Department of Neurosurgery, 
2Brain Tumor Research Laboratory, 
Chonnam National University 
Research Institute of Medical Science, 
Chonnam National University  
Hwasun Hospital and Medical School,  
Gwangju, Republic of Korea
*These authors contributed equally to 
this work.
Correspondence: Shin Jung 
Department of Neurosurgery, Chonnam 
National University Hwasun Hospital, 
160 Ilsim-ri, Hwasun-eup, Hwasun-gun, 
Jeollanam-do 519-809, Republic of Korea 
Tel +82 61 379 7666 
Fax +82 61 379 7673 
Email sjung@chonnam.ac.kr
Background: Celecoxib, a cyclo-oxygenase (COX)-2 inhibitor, has been reported to mediate 
growth inhibitory effects and to induce apoptosis in various cancer cell lines. In this study, we 
examined the potential effects of celecoxib on glioma cell proliferation, migration, and inhibition 
of COX-2 expression in vitro.
Methods: Celecoxib was incorporated into poly DL-lactide-co-glycolide (PLGA) nanoparticles 
for antitumor drug delivery.
Results: PLGA nanoparticles incorporating celecoxib had spherical shapes and their particle 
sizes were in the range of 50–200 nm. Drug-loading efficiency was not significantly changed 
according to the solvent used, except for acetone. Celecoxib was released from the PLGA 
nanoparticles for more than 2 days, and the higher the drug content, the longer the duration of 
drug release. PLGA nanoparticles incorporating celecoxib showed cytotoxicity against U87MG 
tumor cells similar to that of celecoxib administered alone. Furthermore, celecoxib did not 
affect the degree of migration of U87MG cells. PLGA nanoparticles incorporating celecoxib 
showed dose-dependent cytotoxicity similar to that of celecoxib alone in C6 rat glioma cells. 
Western blot assay of the C6 cells showed that neither celecoxib alone nor PLGA nanoparticles 
incorporating celecoxib affected COX-2 expression.
Conclusion: PLGA nanoparticles incorporating celecoxib had antitumor activity similar to 
that of celecoxib alone, even though these particles did not affect the degree of migration or 
COX-2 expression in the tumor cells.
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Introduction
Cyclo-oxygenase (COX)-2 is the key enzyme in arachidonic acid metabolism   resulting 
in prostaglandin production, and is induced by several factors, such as growth   factors, 
cytokines, and tumor promoters. It is thus an inducible enzyme responsible for 
prostaglandin production at sites of inflammation and is involved in cell proliferation.1–5 
In particular, COX-2 expression and prostaglandin production are associated with 
tumorigenesis and tumor progression. Expression of COX-2 has been reported to be 
associated with the complex changes observed in a variety of diseases of the brain. 
Following trauma, an increase in prostaglandin levels can lead to vascular damage. 
In glioblastoma cells, inhibitors of eicosanoid biosynthesis suppress proliferation 
and   promote astrocytic differentiation.6 COX-2 expression has also been detected in 
  colorectal, gastric, esophageal, and lung carcinomas, as well as in brain tumors.7–13 
COX-2 has been reported to be important in the relationship between increased 
  prostaglandin synthesis and the development of glioma and its progression.14,15
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Celecoxib, a selective COX-2 inhibitor, has been reported 
to mediate growth inhibitory effects and to induce apoptosis 
in various cancer cell lines.10–13 Selective COX-2 inhibitors, 
such as celecoxib, have attracted interest as being safe and 
effective anticancer agents. The aim of this study was to 
encapsulate celecoxib into polylactide-co-glycolide (PLGA) 
nanoparticles and to evaluate their antitumor activity 
in glioma cells. Biodegradable nanoparticles have been 
extensively investigated in drug delivery systems.16–18 Due 
to their small particle size, they are attracted to their target 
tissues and have the advantages of targeted drug delivery to 
the desired site of action, prolonged blood circulation of the 
encapsulated drug, and reduced drug side effects.19–21 We 
also investigated the physicochemical properties of PLGA 
nanoparticles incorporating celecoxib, and their antitumor 
activity was studied using glioma cell lines. The potential 
effects of this selective COX-2 inhibitor on glioma cell 
  proliferation, migration, and inhibition of COX-2 expression 
were also examined in vitro. We expected that selective 
COX-2 inhibitor and its nanoparticles would be able to inhibit 
migration and proliferation in glioma cell lines.
Materials and methods
Materials
PLGA was purchased from Boehringher Ingelheim 
(Ingelheim, Germany). A dialysis membrane with a molecular 
weight cutoff of 12,000 g/mol was purchased from Spectra/Por 
(Rancho Dominguez, CA). Dimethylformamide, dimethylac-
etamide, tetrahydrofuran, dimethylsulfoxide, 1,4-  dioxane, 
and acetone of high-pressure liquid chromatography grade 
were purchased from Sigma-Aldrich Chemical Company Ltd 
(St Louis, MO). All other   chemicals and reagents were used 
as extra reagent grade in all experiments.
Preparation of PLGA nanoparticles 
incorporating celecoxib
PLGA nanoparticles incorporating celecoxib were prepared 
as described in a previous report22 with brief modification 
(Figure 1C). When acetone and tetrahydrofuran were used 
as the preparation solvents, 40 mg of PLGA was dissolved in 
7 mL of solvent, and 5 mg of celecoxib was then added to 
this solution, which was poured into 10 mL of deionized 
water to form nanoparticles and stirred for 15 minutes. The 
solvent was evaporated using a rotary evaporator (Rotary 
Vacuum Evaporator, Type N-N, Eyela, Rikakikai Company 
Ltd, Tokyo, Japan) under reduced pressure for 30 minutes. 
The residual solvent was then removed by a dialysis method 
(dialysis tube molecular weight cutoff 12,000 g/mol) for 
9 hours. The dialyzed solution was harvested, and the volume 
of nanoparticle solution was adjusted to 40 mL, ie, 1 mg 
polymer/mL water. This solution was lyophilized and used 
for analysis.
Using dimethylsulfoxide, dimethylformamide, dimethy-
lacetamide, and 1,4-dioxane as solvents, 40 mg of PLGA and 
5 mg of celecoxib were dissolved in 7 mL of solvent, and 
were then poured into 10 mL of deionized water following 
stirring for 10 minutes. The organic solvent was removed 
using dialysis tubing for 24 hours. During the dialysis 
procedure, the deionized water was exchanged every 2 hours. 
The dialyzed solution was then harvested and the volume of 
the nanoparticle solution was adjusted to 40 mL. This   solution 
was lyophilized and used for analysis.
Empty PLGA nanoparticles were prepared without 
addition of celecoxib using dimethylformamide, and the same 
procedure was then used to make the nanoparticles.
Drug concentration, drug content, and drug loading 
  efficiency was determined by ultraviolet spectrophotometry.23 
The volume of the dialyzed nanoparticle solution was adjusted 
to 40 mL with deionized water (ie, 40 mg of PLGA/40 mL 
of water), and 100 µL of adjusted solution was diluted 
with dimethylsulfoxide. The celecoxib concentration was 
measured at 254 nm using an ultraviolet spectrophotometer 
(UV1200, Shimadzu, Tokyo, Japan). For the blank test, an 
empty PLGA nanoparticle solution was adjusted to 40 mL 
(ie, 40 mg of PLGA/40 mL of water), and 0.1 mL of this 
solution was diluted with dimethylsulfoxide. All experiments 
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Figure 1 (A) Chemical structure of PLGA and (B) celecoxib. Schematic illustrations 
of formation of PLGA nanoparticles incorporating celecoxib by nanoprecipitation. 
Celecoxib is molecularly dispersed in the matrix of the nanoparticles.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2622
Kim et alInternational Journal of Nanomedicine 2011:6
were performed in triplicate. The equations for drug content 
and drug loading efficiency are as follows:
Drugcontentw w
Amountof celecoxibinnanoparticles
Weighto
(%, /)
=
f fn anoparticles
× 100
Loadingefficiency w/w
Residualamountof celecoxibinnanopa
(%, )
=
r rticles
Feedingamountof celecoxib
× 100
The drug release test was performed as follows: the 
volume of dialyzed solution was adjusted to 40 mL, and 
5 mL of the adjusted solution was introduced into a dialysis 
tube. After that, the dialysis tube was put into a bottle with 
95 mL of phosphate-buffered solution. The release test was 
performed at 37°C at a stirring rate of 50 rpm. Whole media 
were discarded at specific time intervals and replaced with 
fresh phosphate-buffered solution to prevent drug saturation. 
The amount of celecoxib released was evaluated at 254 nm 
by ultraviolet-visible spectrophotometry.
Transmission electron microscopy 
observations
For transmission electron microscopy, a drop of nanoparticle 
suspension containing 0.05% (w/v) of phosphotungstic acid 
was placed on a transmission electron microscopy copper 
grid coated with carbon film and dried at room temperature. 
Observation was performed at 80 kV using a JEM-2000 FX II 
(JEOL, Peabody, MA).
Measurement of particle size
Measurement of nanoparticle size (concentration 0.1 wt%) 
was performed using photon correlation spectroscopy 
(Zetasizer 3000; Malvern Instruments, Worcestershire, UK) 
with a He-Ne laser beam with a wavelength of 633 nm at 
25°C (scattering angle of 90°).
X-ray powder diffraction
Crystallinity of the drug and the nanoparticles was determined 
using X-ray powder diffraction (Rigaku D/Max-1200; Rigaku 
Americas Corporation, The Woodlands, TX) with   Ni-filtered 
CuK radiation (40 kV , 20 mA). The conditions used for X-ray 
powder diffraction measurement were as follows: data type, 
binary; goniometer, 1; attachment, 1; scan mode, continuous; 
mode 2 (R/T), reflection; scan axis, 2-theta/theta; start angle, 
10.000; stop angle, 80.000; scan speed, 5.000; sampling 
interval, 0.050; theta angle, 5.000; 2 theta angle, 10.000; 
fixed time, 0.01; full scale, 1000; counting unit, CPS; target, 
Cu; wavelength Ka1 1.540510; wavelength Ka 1.544330; 
wavelength Ka 1.541780; wavelength Kb 1.392170 40.0 kV 
and 20.0 mA. Celecoxib, empty PLGA nanoparticles, and 
PLGA nanoparticles incorporating celecoxib were inves-
tigated by X-ray powder diffraction. A 90 mg sample of 
empty nanoparticles was mixed with 10 mg of celecoxib as 
a physical mixture.
Cells
Brain tumor cell lines, including U87MG and C6 rat glioma 
cells, were obtained from the American Type Culture 
Collection (Rockville, MD). The cells were maintained in 
minimum essential medium containing 10% fetal bovine 
serum in a CO2 incubator (5% CO2 at 37°C).
Western blot assay
COX-2 expression was checked using C6 rat glioma cells 
in vitro.9,11,24 The cells were grown in 6 cm culture dishes and 
treated or not treated with the COX-2 inhibitor for 1 day. The 
cells were then washed with cold phosphate-buffered solution 
and homogenized in Tris-HCl buffer (pH 7.4) containing 
0.5% NP-40 and protease inhibitors (Boehringer Mannheim, 
Indianapolis, IN). Samples containing 50 µg of protein and 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
loading buffer with 5% α-mercaptoethanol were heated 
for 5 minutes at 100°C, and loaded on 8%   polyacrylamide 
gel (Bio-Rad, Hercules, CA). Electrophoretic transfer 
to   membranes (Millipore, Bedford, MA) was followed 
by immunoblotting with an antimouse COX-2 antibody 
(BD Transduction Laboratories, Lexington, KY). This 
was followed by hybridization using a secondary antibody 
  conjugated with peroxidase (Amersham Pharmacia Biotech, 
Piscataway, NJ). The signal was detected by chemilumi-
niscence using the ECL-Plus detection system (Amersham 
Pharmacia Biotech).
Cell proliferation assay
The effect of celecoxib and PLGA nanoparticles incorporat-
ing celecoxib on cell growth was determined using a MTT 
cell proliferation assay.25 Celecoxib was dissolved in 100% 
dimethylsulfoxide as a stock solution (40 mg/mL) and then 
diluted 200 times using minimum essential medium. The 
final dimethylsulfoxide concentration was maintained at less 
than 0.5% (v/v). Dimethylsulfoxide 0.5% (v/v) in minimum 
essential medium was used as a control. PLGA nanoparticles 
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incorporating celecoxib were distributed and diluted with 
minimum essential medium. Glioma cell lines are seeded at 
a density of 5 × 103 per well in 96-well plates with minimum 
essential medium containing 10% fetal bovine serum and 
incubated overnight in a CO2 incubator (5% CO2 at 37°C). 
After that, fresh medium containing drug or nanoparticles are 
added. After incubation for the desired period, a MTT Cell 
Titer 96 cell proliferation assay was performed. Absorbance 
was measured at 560 nm using a microtiter plate reader 
(Thermomax; Molecular Devices, San Jose, CA).
Migration assay
A migration assay using the U87MG cell line was   performed 
using a simple scratch technique.25 Briefly, the cell   culture 
media was replaced with medium containing 5 mM 
hydroxyurea to eliminate any confounding effects of the 
experimental agents on cell proliferation. Twenty-four hours 
of treatment with hydroxyurea 5 mM resulted in complete 
inhibition of cell proliferation.
After 24 hours of hydroxyurea treatment, the cultures 
are scraped with a single-edged razor blade. The cells were 
washed twice with phosphate-buffered solution and placed 
in medium containing hydroxyurea and celecoxib of various 
concentrations. After 48 hours of incubation, the cells were 
washed twice with phosphate-buffered solution, fixed in 
absolute alcohol, and stained with 0.1% toluidine blue.
Three microscopic fields were evaluated for each wound 
injury. The number of cells migrating across the wound 
edge and the maximum distance migrated (wound edge 
to nucleus of most distant cell) were determined in each 
field and averaged for each injury. These experiments were 
repeated three times.
Results and discussion
Characterization of PLGA nanoparticles 
incorporating celecoxib
PLGA nanoparticles incorporating celecoxib were prepared 
by nanoprecipitation and a dialysis method using various 
solvents, whereby celecoxib and the polymer dissolved 
in a solvent were precipitated into water and the organic 
  solvent was removed by evaporation or a dialysis procedure 
(Figure 1C). Nanoprecipitation is a widely used method for 
nanoparticle preparation.16,26 Various factors, such as drug 
and polymer solubility in an organic solvent, particle size, 
particle morphology, and aqueous solubility of the organic 
solvent, can affect drug-loading efficiency.20–24 Various 
  solvents were used for preparation of the PLGA nanopar-
ticles incorporating celecoxib to identify the best solvent. 
  Volatile solvents, such as acetone and tetrahydrofuran, are 
easily removed by evaporation. However, other solvents, 
such as dimethylformamide, dimethylsulfoxide, dim-
ethylacetamide, and 1,4-dioxane, are difficult to remove 
by evaporation, so were removed using a dialysis method. 
Figure 2A shows the size distribution of the PLGA nanopar-
ticles incorporating celecoxib. As shown in Figure 1, PLGA 
nanoparticles incorporating celecoxib showed a narrow size 
distribution of 50–200 nm and the average particle size was 
about 92 nm. The morphology of these nanoparticles was 
observed by transmission electron microscopy, as shown 
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Figure  2  (A) Typical  particle  size  measured  by  dynamic  light  scattering  and 
(B) morphology of PLGA nanoparticles incorporating celecoxib (acetone, 40/5 in 
Table 1) observed by transmission electron microscopy.
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in Figure 2B, and they were found to have spherical shapes 
and particle sizes around 100 nm. This result is similar to 
the particle size data shown in Figure 2A.
The effects of various solvents on nanoparticle formation 
are summarized in Table 1. Changes in the solvent used had 
little effect on the physicochemical properties of the nano-
particles, such as particle size and drug loading efficiency. 
The size of the PLGA nanoparticles incorporating celecoxib 
was about 100 nm for almost all of the samples. However, the 
size of the nanoparticles increased when tetrahydrofuran was 
used as the solvent. When the feeding amount of drug was 
increased, the particle size also increased slightly. Because 
the distribution of nanoparticles in the body is significantly 
influenced by particle size,17,27 small-sized nanoparticles 
are preferred for intravenous administration. In particular, 
particles smaller than 200 nm are considered acceptable for 
passive drug targeting.27,28
When acetone and tetrahydrofuran was used as the 
  solvents, drug content and loading efficiency were relatively 
higher than for the other solvents, possibly because the drug 
is easily liberated from dialysis tubing during the dialysis 
procedure, whereas nonvolatile solvents, such as dimeth-
ylformamide, dimethylsulfoxide, dimethylacetamide, and 
1,4-dioxane, require a longer period of dialysis to remove the 
organic solvent. The drawbacks of the dialysis method are 
the ease of drug release from the dialysis membrane before 
and after nanoparticle formation. When the drug feeding 
amount was increased, the drug content also increased, but 
the drug loading efficiency decreased.
Figure 3 shows the X-ray powder diffraction data for 
PLGA nanoparticles incorporating celecoxib. Celecoxib 
showed intrinsic crystalline peaks (Figure 3A), while 
the empty nanoparticles showed broad peak properties 
 ( Figure 3B). PLGA nanoparticles incorporating   celecoxib 
had peak characteristics very similar to those of the 
empty nanoparticles (Figure 3C), indicating that drug was 
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Figure 3 X-ray powder diffraction patterns for PLGA nanoparticles incorporating 
celecoxib.  (A)  Celecoxib,  (B)  empty  nanoparticles,  (C)  PLGA  nanoparticles 
incorporating celecoxib (drug content 7.8%, w/w), (D) drug content 10.5%, w/w, 
and (E) a physical mixture of celecoxib and empty nanoparticles (1/10, w/w). 
Note: The data show that celecoxib was molecularly dispersed in the nanoparticle 
matrix at a lower drug content, and aggregated or crystallized at a higher drug content.
Table 1 Characterization of PLGA nanoparticles incorporating celecoxib according to organic solvent used
Solvent  
used
Weight ratio of  
PLGA/CEL (mg/mg)
Drug contents (%, w/w) Loading  
efficiency  
(%, w/w)
Particle size (nm)
Theoretical Experimental Intensity, mean Weight, mean Number, mean
Acetone 40/5 11.11 7.8 67.6 117.4 ± 36.1   91.9 ± 25.2   78.7 ± 16.4
40/10 20.0 10.5 47.0 172.5 ± 59.1 132.7 ± 46.3 110.7 ± 30.1
THF 40/5 11.11 6.3 54.0 255.5 ± 63.5 213.6 ± 51.7 186.5 ± 37.2
DMSO 40/5 11.11 3.8 31.6 105.0 ± 64.0   80.5 ± 20.5   70.3 ± 7.6
DMAc 40/5 11.11 4.2 35.1 150.7 ± 113.3 100.7 ± 70.6   87.4 ± 29.2
1,4-dioxane 40/5 11.11 4.4 36.8 164.5 ± 58.5 125.4 ± 39.3 102.3 ± 24.3
DMF 40/5 11.11 4.2 35.1 115.1 ± 32.6   96.8 ± 29.3   80.7 ± 21.4
Abbreviations: CEL, celecoxib; DMSO, dimethylsulfoxide; DMF, dimethylformamide; DMAc, dimethylacetamide; THF, tetrahydrofuran.
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incorporated inside the nanoparticles. However, when the 
feeding amount of drug was increased, drug crystalline 
peaks were observed (Figure 3D), indicating that some of 
the free drug might have been crystallized in the matrix of 
the nanoparticles. As shown in Figure 3E, a physical mixture 
of empty nanoparticles and drug showed intrinsic peaks for 
both the empty nanoparticles and the drug. At low content, the 
drug could exist as a molecular dispersion in the nanoparticle 
matrix and its intrinsic crystalline peaks would disappear. 
However, drug can be aggregated at a higher drug loading, 
and crystalline peaks can be observed.19 Tan et al reported on 
a silica-lipid hybrid incorporating celecoxib microcapsules 
for oral drug delivery.29 They described similar results for 
X-ray powder diffraction, ie, the microcapsules   incorporating 
celecoxib showed a broad spectrum, while the drug itself 
showed sharp intrinsic crystalline peaks.
Drug release study
Figure 4 shows the effect of the solvent used on release 
of celecoxib from the nanoparticles. An initial burst was 
observed for about 4 hours, and then the drug was released in 
a controlled manner over a period of 2 days. When acetone or 
tetrahydrofuran was used as the preparation solvent, celecoxib 
was released at a slower rate than with the other solvents. 
This finding might be due to the fact that the drug content 
achieved using acetone and tetrahydrofuran was higher than 
for the other solvents. Generally, a hydrophobic drug can be 
crystallized into nanoparticles, thereby achieving a higher 
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Figure 4 Effect of solvent used on drug release from the PLGA nanoparticles. Solvents used for preparation of the nanoparticles were (A) acetone and tetrahydrofuran and 
(B) dimethylsulfoxide, dimethylacetamide, 1,4-dioxane, and dimethylformamide. The properties of the PLGA nanoparticles are shown in Table 1.
Abbreviations: THF, tetrahydrofuran; DMSO, dimethylsulfoxide; DMAc, dimethylacetamide; DMF, dimethylformamide.
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Figure 5 Effect of drug contents on celecoxib release from the PLGA nanoparticles.
drug content.19 The release rate for a crystallized drug in nano-
particles is relatively slow compared with that for a molecular 
dispersion of drug in nanoparticles. At a lower drug content, 
the drug can exist as a molecular dispersion, and crystalline 
peaks for celecoxib are not seen on X-ray powder diffraction 
measurement. Particle size is another factor affecting drug 
release kinetics. It has been reported that larger nanopar-
ticles have a slower drug release rate than smaller ones.16,20 
Figure 5 shows the effect of drug content on its release rate 
from nanoparticles. The higher the drug content, the slower 
the release rate of the drug. At higher drug feeding, the drug 
can be crystallized in the nanoparticles, and this was supported 
by our X-ray powder diffraction findings.
Tan et al reported that the drug release rate can be changed 
by concentration of the surfactant, using sodium lauryl sulfate 
and other formulation materials. They reported that silica-
lipid hybrid microcapsules were effective for enhancing drug 
dissolution properties and increasing the drug half-life in 
plasma.29 Thakkar et al reported that celecoxib incorporated 
into albumin microspheres was released over about 1 week.23 
Furthermore, they also observed an initial burst effect for 
12 hours, ie, more than 50% (w/w) of the drug was released 
in the first 12 hours. Ayalasomayajula and Kompella reported 
on their construction of PLGA microspheres containing 
celecoxib using an oil/water emulsion solvent evaporation 
method.30 They reported that celecoxib was released from the 
microspheres over 49 days, and that less than 40% of the drug 
was released during this period. However, a mean nanoparticle 
diameter smaller 300 nm may enable faster drug release than 
from microspheres, ie, more than 80% (w/w) of the drug was 
released from PLGA nanoparticles incorporating celecoxib.31 
In our experiment, drug release continued over 1 day, sug-
gesting that drug release from nanoparticles can change 
significantly according to the polymer properties, particle 
size, and particle morphology. Nanoparticles incorporating 
celecoxib were successively prepared during this experiment, 
and we used celecoxib nanoparticles prepared from acetone 
in a subsequent study (drug content, 10.5%, w/w).
Antitumor activity of PLGA nanoparticles 
incorporating celecoxib
COX-2 expression in the brain is enhanced in the presence of 
inflammatory disorders, trauma, ischemia, and Alzheimer’s 
disease.32–35 It has been reported that COX-2-positive cells 
accumulate in areas of necrosis.36,37 This could represent 
induction of COX-2 in tumor cells by hypoxia or by factors 
released at the sites of necrosis. Increased levels of prosta-
glandins are due to COX-2 overexpression. This has been 
previously reported in colon and human brain tumor tissues 
when compared with normal tissue,36–38 suggesting that pros-
taglandins play a role in tumor development. Thus, COX-2 
inhibitors may lead to a reduction in prostaglandin levels 
which, in turn, may inhibit proliferation and migration, and 
induce apoptosis in glioma cell lines. A similar effect has been 
reported in colon, esophageal, and pancreatic carcinoma cell 
lines, where a selective COX-2 inhibitor was shown to inhibit 
proliferation and to induce apoptosis.11–13,39,40 Treatment of 
brain tumors using celecoxib, a selective COX-2 inhibitor, 
is expected to improve the treatment of this type of tumor, 
as well as improve quality of life for patients.
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tumor cell growth. These results indicate that nanoparticles 
incorporating celecoxib have similar antitumor activity to 
that of celecoxib alone. The effect of celecoxib on migration 
was studied in a two-dimensional culture system, as shown in 
Figure 7. U87MG cells were grown to confluence in a 6 cm 
culture dish, and half of the cultured cell area was removed 
following treatment overnight with hydroxyurea, then 
exposed to different concentrations of celecoxib.   Figure 7A 
shows images of tumor cell migration and   Figure 7B shows 
the migration distance. Migration of U87MG cells in this 
two-dimensional system was not significantly changed by any 
concentration of celecoxib, while cell growth was slightly 
changed at higher concentrations. These results indicate that 
migration of U87MG cells is not significantly inhibited by 
COX-2 inhibition, even though cell proliferation was affected 
by treatment with celecoxib.
Figure 8 shows the effect of celecoxib and PLGA 
nanoparticles incorporating celecoxib on the growth of C6 
rat glioma cells. Both celecoxib and PLGA nanoparticles 
incorporating celecoxib showed similar cytotoxicity against 
C6 cells in a dose-dependent manner. Empty PLGA nanopar-
ticles did not affect tumor cell growth. A Western blot assay 
was used to investigate whether or not celecoxib inhibited 
COX-2 expression in C6 cells. As shown in Figure 9, COX-2 
expression in C6 cells was not significantly suppressed 
by treatment with celecoxib or the nanoparticles. In other 
reports, expression of COX-2 protein was also not specifi-
cally inhibited by celecoxib.41,42 Barnes et al41 reported that 
COX-2 protein expression was decreased by treatment with 
celecoxib. However, it seems that the decreased COX-2 
expression and antiproliferative effect of celecoxib treatment 
is more related to apoptosis of tumor cells rather than specific 
inhibition of COX-2 expression by celecoxib.41,42 Celecoxib 
is known to inhibit expression of non-COX-2 targets, such as 
carbonic anhydrases, 3-phosphoinositide-dependent protein 
kinase-1, sarcoplasmic/endoplasmic reticulum, and calcium 
ATPase in tumor cells. Furthermore, celecoxib is known to 
increase apoptosis of tumor cells via inactivation of Akt, 
which is a member of the serine/threonine kinase family. Our 
results indicate that inhibition of proliferation of tumor cells 
by celecoxib is not closely related to COX-2 expression. Even 
if celecoxib or PLGA nanoparticles incorporating celecoxib 
did not significantly affect COX-2 expression and tumor cell 
mobility, nanoparticles had the same antiproliferative effect 
on brain tumor cells.
To test the stability of celecoxib in the nanoparticle 
matrix, PLGA nanoparticles incorporating celecoxib was 
recovered at 24 hours in the drug release experiment and used 
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Figure  6  Cytotoxicity  of  PLGA  nanoparticles  incorporating  celecoxib  against 
brain tumor cells. Different concentrations of celecoxib and PLGA nanoparticles 
incorporating celecoxib were treated for (A) 1 day, (B) 2 days, and (C) 4 days against 
U87 tumor cells. 
Notes: Data points represent the mean from eight replicate wells and the bars indicate 
the standard deviation of the mean. Values were calculated relative to the control 
(0.1% dimethylsulfoxide). Absorbance of sample/absorbance of control × 100.
To evaluate the antitumor activity of celecoxib, glioma 
cells were treated with PLGA nanoparticles incorporating 
celecoxib or celecoxib alone. As shown in Figure 6,   celecoxib 
and PLGA nanoparticles incorporating celecoxib showed sim-
ilar cytotoxicity, whereas empty nanoparticles did not affect 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2628
Kim et alInternational Journal of Nanomedicine 2011:6
0
200 04 00 6008 00
Distance (µm)
C
e
l
l
 
n
u
m
b
e
r
1000 1200
Control
10 µM
1400
20
40
60
80
100
50 µM
100 µM
B A 100 50
10 Control
Figure 7 (A) Effect of various concentrations of celecoxib on migration of U87MG cells (in µM). U87MG cells confluently filled a 6 cm culture dish, and half of the area of the 
cultured cells was removed by a knife following overnight treatment with hydroxyurea and exposed to different concentrations of celecoxib. (B) Comparison of migration 
ability in an in vitro assay after treatment with a range of celecoxib concentrations.
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Figure 8 Cytotoxicity of PLGA nanoparticles incorporating celecoxib against C6 rat 
glioma cells. Different concentrations of celecoxib and PLGA nanoparticles incorporating 
celecoxib were used for (A) 1 day and (B) 2 days to treat C6 tumor cells. 
Notes: Data points represent the mean for eight replicate wells and bars indicate 
the standard deviation of the mean. The value was calculated relative to control   
(0.1% dimethylsulfoxide). Absorbance of sample/absorbance of control × 100.
Figure 9 Western blot analysis for COX-2 protein in C6 rat glioma cells. Each lane is as 
follows: C6 cells treated with celecoxib or PLGA nanoparticles incorporating celecoxib.
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Figure 10 Cytotoxicity of PLGA nanoparticles incorporating celecoxib recovered 
from drug release experiment against U87MG cells (A) and C6 rat glioma cells (B). 
During the drug release experiment, PLGA nanoparticles incorporating celecoxib 
were harvested at 24 hours and dissolved in dimethylsulfoxide, and the harvested 
celecoxib  solution  was  diluted  with  cell  culture  medium. A  calculated  amount 
(50 µg/mL) of celecoxib was used to treat the tumor cells.
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to treat the tumor cells, as shown in Figure 10. The celecoxib 
recovered in the nanoparticles showed similar antitumor 
activity against U87MG cells (Figure 10A) and C6 cells 
(Figure 10B), indicating that the intrinsic stability and anti-
tumor activity of celecoxib was not significantly changed 
during the drug release experiment. The results of our study 
show that PLGA nanoparticles incorporating celecoxib are 
promising candidates for antitumor drug delivery.
Conclusion
PLGA nanoparticles incorporating celecoxib were prepared 
for antitumor drug delivery. PLGA nanoparticles incorporat-
ing celecoxib had spherical shapes and their particle sizes 
were in the range of 50–200 nm. Drug-loading efficiency 
was not significantly altered according to the solvent used, 
except for acetone. The drug was released for longer than 
2 days from PLGA nanoparticles. The higher the drug 
content, the longer the duration of drug release. PLGA 
nanoparticles incorporating celecoxib showed almost the 
same cytotoxicity against U87MG tumor cells as celecoxib 
itself. Furthermore, celecoxib did not affect the degree of 
migration of U87MG cells. When C6 rat glioma cells were 
used, PLGA nanoparticles incorporating celecoxib showed 
dose-dependent cytotoxicity similar to that of celecoxib itself. 
Neither celecoxib nor PLGA nanoparticles incorporating 
celecoxib affected COX-2 expression in C6 cells on Western 
blot assay. In conclusion, PLGA nanoparticles incorporating 
celecoxib have similar antitumor activity to celecoxib itself, 
even if they did not affect the degree of migration or COX-2 
expression in tumor cells.
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